Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 9/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | SUV39H1 | O43463 | 3/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.39 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126665 | 0.92 | RAF1 (0.48) | FBP1EPHB2MKNK1EGFRSUV39H1 | |
| SCHEMBL7128555 | 0.92 | EGFR (0.47) | FBP1EPHB2MKNK1EGFRERBB2 | |
| SCHEMBL7127858 | 0.84 | EGFR (0.58) | EGFRERBB2 | |
| SCHEMBL7128560 | 0.84 | RAF1 (0.54) | FBP1EPHB2MKNK1EGFRERBB2 | |
| SCHEMBL7126660 | 0.78 | FBP1 (0.45) | FBP1EPHB2MKNK1EGFRERBB2 | |
| SCHEMBL7241072 | 0.77 | KDR (0.61) | EPHB2EGFRERBB2ERBB4RIPK2 | |
| SCHEMBL7127189 | 0.76 | EGFR (0.66) | EGFRERBB2ERBB4 | |
| SCHEMBL7237990 | 0.74 | EGFR (0.44) | EGFRERBB2SUV39H1PRMT1TTBK1 | |
| SCHEMBL7241721 | 0.73 | EGFR (0.64) | EGFRERBB2ERBB4CSF1RTTBK1 | |
| SCHEMBL7128556 | 0.72 | EGFR (0.47) | FBP1EPHB2MKNK1EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | claimed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | FBP1 4232/4885EPHB2 320/4885MKNK1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.